Home > Childhood cancer Info > We fund research > For researchers > International Childhood Cancer Conference 2019

International Childhood Cancer Conference 2019

Children with Cancer UK is the leading UK charity dedicated to the fight against childhood cancer.
We were delighted to hold our annual conference Childhood Cancer 2019 at Newcastle University on 9-10th September 2019.

Watch all the videos from the conference.

Exploiting genomic medicine throughout the patient journey.

Newcastle, 9th & 10th September 2019

Copthorne Hotel Newcastle, The Close, Quayside, Newcastle upon Tyne, NE1 2RT

Please watch our video to find out more.

A medical and scientific educational update on how genomic medicine is being used to deliver new therapies, reduce toxicity, enable early diagnosis and progress efforts to prevent cancer in children, teenagers and young adults.

Chaired by Professor Steve Clifford of Newcastle University and Dr Nick Goulden on behalf of Children with Cancer UK, key areas to be discussed in the meeting include:

Clinical Delivery Intiatives

100k genome GECIPS SMPaeds & INSTINCT Phase I/II networks
Speakers: Professors Steve Clifford, Adrienne Flannagan, Anthony Moorman, Darren Hargrave & Dr Lynley Marshall

Solid Tumour Biology Update

Brain Tumours, Neuroblastoma, Lymphoma
Speakers: Professor Chris Jones, Dr Sally George, Dr Simon Bomken

Immunotherapy and Tumour Microenvironment

CAR- T in Solid Tumours & Leukaemia, Senescence
Speakers: include Dr Karin Straathof and Dr Sara Ghorashian

Survivorship

QOL in Brain Tumours, Scope for prospective intervention
Speakers: include Dr Rod Skinner, Dr Sara Watts

Early Diagnosis and Screening

AML in Down syndrome , circulating DNA, NGS for detection of MRD
Speakers: include Dr John Moppett

Causation and Epidemiology

Update from Childhood Cancer 2018, Children with Cancer UK causation grant round
Speakers: Trustee Alasdair Philips, Professor Denis Henshaw

Genomic Medicine in Low- and Middle-Income Countries

Speakers: include Professor Simon Bailey, Dr Vikki Rand

Plenary lecture

Evolution of Cancer Genetics, Professor Christine Harrison Newcastle University

Programme

Childhood Cancer 2019: Exploiting genomic medicine throughout the patient journey

Day 1 – Monday 9th September 2019

Day 2 – Tuesday 10th September 2019

Full details of Programme

Abstracts

Thank you for your submissions

View the Book of Abstracts

Conference organising committee

Professor Steven Clifford BSc, PhD(Cancer Molecular Biology)
Professor of Molecular Paediatric Oncology and Director, Northern Institute for Cancer Research, Newcastle University.
Professor Clifford’s research is focussed on understanding the biological basis of embryonal brain tumour development (principally medulloblastoma) and response to therapy, and translating these findings into improved clinical treatments.  He plays leading roles in national (CCLG, NCRI) and international (SIOP-Europe) research networks and clinical trials in medulloblastoma, and directs the UK national reference centre for medulloblastoma molecular diagnostics.

Professor Anthony Moorman, BSc, MSc, PhD (Epidemiology)
Professor of Genetic Epidemiology, Northern Institute for Cancer Research, Newcastle University.
Anthony Moorman has worked in the field of leukaemia genetics for more than 25 years and, along with the other members of the Leukaemia Research Cytogenetics Group (LRCG), has been involved in the discovery, characterisation and clinical assessment of numerous genetic biomarkers in acute lymphoblastic and myeloid leukaemia. More recently, Anthony’s research has focussed on integrating risk factors to assist the design of novel risk stratification algorithms.

Dr Nick Goulden MB, ChB, MRCP, FRCPath, PhD
Medical Research Director, Children with Cancer UK.
Nick Goulden retired from Great Ormond Street Hospital, where he was a Consultant in Paediatric Haematologyin December 2015. He subsequently took up the role of Medical Research Director at Children with Cancer UK on a consultancy basis.Nick was instrumental in incorporating the detection of minimal residual disease (MRD) into treatment stratification for childhood acute lymphoblastic leukaemia (ALL).

Sign up to our Researchers’ mailing list
Send us an email